HighTower Advisors LLC Has $6.55 Million Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• HighTower Advisors cut its Boston Scientific stake by 26.9% in the second quarter, selling 56,467 shares and retaining 153,501 shares valued at approximately $6.55 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific reported quarterly earnings of $0.86 per share, beating estimates by $0.03, while revenue rose 7.5% year over year to $5.44 billion. The company also authorized a $5 billion share-repurchase program, covering up to 6.4% of outstanding shares.
• BSX shares opened at $43.03, near their 52-week low, despite a consensus analyst rating of “Moderate Buy” and an average price target of $71.46. Two directors recently purchased shares, contributing to $9.39 million in insider buying over the past 90 days.

HighTower Advisors LLC trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 26.9% in the second quarter, according to its most recent filing with the SEC. The firm owned 153,501 shares of the medical equipment provider's stock after selling 56,467 shares during the period. HighTower Advisors LLC's holdings in Boston Scientific were worth $6,551,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in BSX. CYBER HORNET ETFs LLC boosted its holdings in Boston Scientific by 3.4% during the third quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider's stock valued at $391,000 after purchasing an additional 132 shares in the last quarter. Gerber Kawasaki Wealth & Investment Management lifted its position in shares of Boston Scientific by 4.7% during the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider's stock worth $294,000 after buying an additional 139 shares during the period. Northwestern Mutual Investment Management Company LLC lifted its position in shares of Boston Scientific by 0.3% during the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider's stock worth $4,516,000 after buying an additional 140 shares during the period. Kingsview Wealth Management LLC boosted its stake in Boston Scientific by 2.4% in the 4th quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider's stock valued at $578,000 after buying an additional 142 shares in the last quarter. Finally, RiverFront Investment Group LLC boosted its stake in Boston Scientific by 0.7% in the 4th quarter. RiverFront Investment Group LLC now owns 21,308 shares of the medical equipment provider's stock valued at $2,032,000 after buying an additional 150 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Activity

In other news, Director David C. Habiger purchased 2,100 shares of the firm's stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward J. Ludwig acquired 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average price of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders bought 194,522 shares of company stock valued at $9,385,210. Company insiders own 0.34% of the company's stock.

Boston Scientific Trading Down 4.3%

Shares of NYSE BSX opened at $43.03 on Friday. Boston Scientific Corporation has a 1-year low of $42.20 and a 1-year high of $105.72. The company has a market cap of $62.36 billion, a PE ratio of 17.42, a P/E/G ratio of 1.04 and a beta of 0.57. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a 50-day moving average of $47.04 and a two-hundred day moving average of $54.74.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the business posted $0.75 earnings per share. Boston Scientific's revenue for the quarter was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has initiated a stock repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company's management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Evercore set a $65.00 price objective on Boston Scientific in a research note on Monday, July 6th. Truist Financial lowered their target price on shares of Boston Scientific from $62.00 to $57.00 and set a "buy" rating on the stock in a report on Thursday, July 30th. Bank of America dropped their target price on shares of Boston Scientific from $105.00 to $68.00 and set a "buy" rating for the company in a research report on Monday, May 18th. Zacks Research downgraded shares of Boston Scientific from a "hold" rating to a "strong sell" rating in a report on Friday, June 5th. Finally, Raymond James Financial restated an "outperform" rating and issued a $57.00 price target on shares of Boston Scientific in a research report on Thursday, July 30th. Twenty-four research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $71.46.

Boston Scientific Company Profile

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.